Sattva Sukun Lifecare FY26 Results: Profit Plummets, Quarterly Loss

Standalone Net Profit FY2026: ₹0.17 crore
Consolidated Net Profit FY2026: ₹0.21 crore

Reader Takeaway: Annual profit decline and quarterly losses contrast with rights issue fund deployment.

What just happened

Sattva Sukun Lifecare Ltd. has announced its audited financial results for the fiscal year ended March 31, 2026. The company reported a standalone net profit of ₹0.17 crore (₹16.52 lakh) for FY2026, a steep decline of approximately 93% from ₹2.49 crore (₹249.02 lakh) in FY2025. On a consolidated basis, net profit was ₹0.21 crore (₹21.17 lakh), also down significantly from ₹2.49 crore (₹248.94 lakh) in the previous year. Furthermore, the company registered net losses for the fourth quarter of FY2026, with a standalone loss of ₹0.57 crore (₹56.97 lakh) and a consolidated loss of ₹0.71 crore (₹70.99 lakh).

Why this matters

The sharp fall in profitability and the occurrence of quarterly losses raise concerns about the company's earnings power and operational efficiency. While the company has actively deployed funds raised from a rights issue, the bottom-line performance indicates challenges in translating investments into profits. Investors will be closely watching for signs of recovery and improved financial performance in upcoming quarters.

The backstory

On July 07, 2025, Sattva Sukun Lifecare raised ₹19.16 crore through a rights issue. As of March 31, 2026, ₹18.60 crore of these funds had been utilized. A significant portion, ₹11.69 crore, was invested in M/s PavaPuri Export Private Limited, a subsidiary. The remaining funds were allocated to working capital, business expansion, and general corporate purposes.

What changes now

Investors will need to assess how the substantial investment in the subsidiary and the deployed working capital contribute to future revenue and profit growth. The focus shifts to the management's ability to navigate the current financial pressures and reverse the trend of declining profitability.

Risks to watch

The primary risks include the continued decline in profitability, the potential for further quarterly losses, and the performance of the subsidiary, M/s PavaPuri Export Private Limited. Investors should monitor the effective utilization of the rights issue proceeds and the company's overall market conditions.

Auditor Remarks

The statutory auditors, M/s. SSRV & Associates, have issued an unmodified opinion on the financial results for the quarter and year ended March 31, 2026. This indicates that the financial statements present a true and fair view, despite the performance concerns.

Context metrics (time-bound)

For the fiscal year 2026:

• Standalone Net Sales: ₹4.22 crore (down from ₹5.26 crore in FY2025)
• Consolidated Net Sales: ₹32.25 crore (up from ₹5.26 crore in FY2025)
• Standalone Net Profit: ₹0.17 crore (down from ₹2.49 crore in FY2025)
• Consolidated Net Profit: ₹0.21 crore (down from ₹2.49 crore in FY2025)

For the quarter ended March 31, 2026:

• Standalone Net Loss: ₹0.57 crore
• Consolidated Net Loss: ₹0.71 crore

What to track next

Investors should track future quarterly results, management commentary on performance improvement strategies, updates on the performance of M/s PavaPuri Export Private Limited, and any further announcements regarding the utilization of remaining rights issue funds.